Each year studies are performed to determine how well Flu Jabs are protecting members of the public from influenza. While each year varies in the strain of influenza circulating and the effectiveness of the vaccine at fighting the specific strains, studies show that flu vaccinations reduce the risk of infection by between 40% to 60%.
Not only do Flu Jabs prevent infection but we can also see how effective they are by looking at the number of serious cases of flu and the number of hospitalisations. With the years in which flu jabs are more effective showing lower rates of hospitalisations and severe cases, in those that are vaccinated.
hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.